Topical corticosteroids and topical calcineurin inhibitors in the treatment of atopic dermatitis: Focus on percutaneous absorption

American Journal of Therapeutics

Volumn 16, Issue 3, 2009, Pages 264-273

  Pariser, David ^a  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

Absorption; Calcineurin inhibitors; Corticosteroids; Penetration; Topical therapy

Indexed keywords

BETAMETHASONE DIPROPIONATE; BETAMETHASONE VALERATE; CALCINEURIN INHIBITOR; CLOBETASOL PROPIONATE; CORTICOSTEROID; DESONIDE; DESOXIMETASONE; DIFLUCORTOLONE; FLUDROXYCORTIDE; FLUOCINONIDE; FLUTICASONE PROPIONATE; HALCINONIDE; HYDROCORTISONE; HYDROCORTISONE BUTYRATE; MOMETASONE FUROATE; PIMECROLIMUS; PREDNICARBATE; TACROLIMUS; TRIAMCINOLONE ACETONIDE; ULOBETASOL PROPIONATE;

ADRENAL INSUFFICIENCY; ADRENAL SUPPRESSION; APPLICATION SITE BURNING; ATOPIC DERMATITIS; BONE NECROSIS; COMORBIDITY; CUSHING SYNDROME; DISEASE SEVERITY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FORMULATION; DRUG PENETRATION; DRUG POTENCY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GROWTH RETARDATION; HUMAN; LAMELLAR ICHTHYOSIS; NONHUMAN; PRIORITY JOURNAL; PYODERMA GANGRENOSUM; REVIEW; SIDE EFFECT; SKIN ABSORPTION; SKIN IRRITATION; SKIN SENSITIVITY; SKIN THINNING; SKINFOLD THICKNESS; TREATMENT DURATION;

ADMINISTRATION, TOPICAL; ADRENAL CORTEX HORMONES; CALCINEURIN; DERMATITIS, ATOPIC; HUMANS; PHARMACISTS; PROFESSIONAL ROLE; SKIN ABSORPTION; TACROLIMUS;

EID: 67249092202     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/MJT.0b013e31818a975c     Document Type: Review

References (64)

1. Callen J, Chamlin S, Eichenfield LF, et al. A systematic review of the safety of topical therapies for atopic dermatitis. Br J Dermatol. 2007;156:203-221. (Pubitemid 46095948)
2. Alomar A, Berth-Jones J, Bos JD, et al. The role of topical calcineurin inhibitors in atopic dermatitis. Br J Dermatol. 2004;151(Suppl 70):3-27. (Pubitemid 40023628)
3. Billich A, Aschauer H, Aszódi A, et al. Percutaneous absorption of drugs used in atopic eczema: pimecrolimus permeates less through skin than corticosteroids and tacrolimus. Int J Pharm. 2004;269:29-35. (Pubitemid 38032821)
4. Hoare C, Li Wan Po A, Williams H. Systematic review of treatments for atopic eczema. Health Technol Assess. 2000; 4:1-191. (Pubitemid 32051337)
5. Turpeinen M, Salo OP, Leisti S. Effect of percutaneous absorption of hydrocortisone on adrenocortical responsiveness in infants with severe skin disease. Br J Dermatol. 1986;115:475-484. (Pubitemid 16025343)
6. Hengge UR, Ruzicka T, Schwartz RA, et al. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol. 2006;54:1-15. (Pubitemid 41832453)
7. Krueger GG, Eichenfield L, Goodman JJ, et al. Pharmacokinetics of tacrolimus following topical application of tacrolimus ointment in adult and pediatric patients with moderate to severe atopic dermatitis. J Drugs Dermatol. 2007;6:185-193.
8. Maibach HI, Wester RC. Issues in measuring percutaneous absorption of topical corticosteroids. Int J Dermatol. 1992;31(Suppl 1):21-25.
9. Habif TB. Clinical Dermatology. 4th ed. St. Louis, MO: Mosby, Inc; 2004.
10. Aalto-Korte K, Turpeinen M. Transepidermal water loss predicts systemic absorption of topical hydrocortisone in atopic dermatitis. Br J Dermatol. 1996;135:497-4:98. (Pubitemid 26297863)
11. Aalto-Korte K, Turpeinen M. Quantifying systemic absorption of topical hydrocortisone in erythroderma. Br J Dermatol. 1995;133:403-408.
12. Turpeinen M, Mashkilleyson N, Bjorksten F, et al. Percutaneous absorption of hydrocortisone during exacerbation and remission of atopic dermatitis in adults. Acta Derm Venereol. 1988;68:331-335. (Pubitemid 18188563)
13. Turpeinen M. Influence of age and severity of dermatitis on the percutaneous absorption of hydrocortisone in children. Br J Dermatol. 1988;118:517-522. (Pubitemid 18166525)
14. Rasmussen JE. Percutaneous absorption of topically applied triamcinolone in children. Arch Dermatol. 1978; 114:1165-1167. (Pubitemid 8406859)
15. Guber HA, Farag AF, Lo J, et al. Evaluation of endocrine function. In: Abraham NZ Jr, Bluth MH, Hutchinson RE, et al, eds. McPherson & Pincus: Henry's Clinical Diagnosis and Management by Laboratory Methods. 21st ed. Philadelphia, PA: WB. Saunders; 2006:1-31.
16. Halverstam CP, Vachharajani A, Mallory SB. Cushing syndrome from percutaneous absorption of 1% hydrocortisone ointment in Netherton syndrome. Pediatr Dermatol. 2007;24:42-45. (Pubitemid 46245618)
17. Fartasch M, Williams ML, Elias PM. Altered lamellar body secretion and stratum corneum membrane structure in Netherton syndrome: differentiation from other infantile erythrodermas and pathogenic implications. Arch Dermatol. 1999;135:823-832. (Pubitemid 29330807)
18. Allen A, Siegfried E, Silverman R, et al. Significant absorption of topical tacrolimus in 3 patients with Netherton syndrome. Arch Dermatol. 2001;137:747-750. (Pubitemid 32577856)
19. Eichenfield LF, Miller BH. Two randomized, double-blind, placebo-controlled studies of fluticasone propionate lotion 0.05% for the treatment of atopic dermatitis in subjects from 3 months of age. J Am Acad Dermatol. 2006; 54:715-717.
20. Hebert AA, Friedlander SF, Allen DB. Topical fluticasone propionate lotion does not cause HPA axis suppression. J Pediatr. 2006;149:378-382. (Pubitemid 44308433)
21. Roeder A, Schaller M, Schafer-Korting M, et al. Safety and efficacy of fluticasone propionate in the topical treatment of skin diseases. Skin Pharmacol Physiol. 2005;18:3-11. (Pubitemid 40082223)
22. Friedlander SF, Hebert AA, Allen DB. Safety of fluticasone propionate cream 0.05% for the treatment of severe and extensive atopic dermatitis in children as young as 3 months. J Am Acad Dermatol. 2002;46:387-393. (Pubitemid 34225403)
23. Stuetz A, Grassberger M, Meingassner JG. Pimecrolimus (Elidel, SDZ ASM 981) - preclinical pharmacologic profile and skin selectivity. Semin Cutan Med Surg. 2001;20: 233-241.
24. Billich A, Aschauer H, Stuetz A. In vitro penetration/permeation of pimecrolimus and tacrolimus from their marketed formulations (Elidel and Protopic). J Invest Dermatol. 2004;122:A40. Abstract 238.
25. Maingassner JG, Aschauer H, Billich A, et al. Skin permeability in pigs is less for pimecrolimus than for tacrolimus under normal and diseased conditions. J Invest Dermatol. 2004;122:A41. Abstract 243.
26. Graham-Brown RA, Grassberger M. Pimecrolimus: a review of pre-clinical and clinical data. Int J Clin Pract. 2003; 57:319-327.
27. Gupta AK, Chow M. Pimecrolimus: a review. J Eur Acad Dermatol Venereol. 2003;17:493-503.
28. Harper J, Smith C, Rubins A, et al. A multicenter study of the pharmacokinetics of tacrolimus ointment after first and repeated application to children with atopic dermatitis. J Invest Dermatol. 2005;124:695-699. (Pubitemid 40489494)
29. Rubins A, Gutmane R, Valdmane N, et al. Pharmacokinetics of 0.1% tacrolimus ointment after first and repeated application to adults with moderate to severe atopic dermatitis. J Invest Dermatol. 2005;125:68-71. (Pubitemid 40981425)
30. Protopic [package insert]. Deerfield, IL: Astellas Pharma US; 2006.
31. Alaiti S, Kang S, Fiedler VC, et al. Tacrolimus (FK506) ointment for atopic dermatitis: a phase I study in adults and children. J Am Acad Dermatol. 1998;38:69-76. (Pubitemid 28100468)
32. Prograf [package insert]. Deerfield, IL: Astellas Pharma US; 2006.
33. Bens G, Boralevi F, Buzenet C, et al. Topical treatment of Netherton's syndrome with tacrolimus ointment without significant systemic absorption. Br J Dermatol. 2003;149: 224-226. (Pubitemid 36966553)
34. Saif GB, Al-Khenaizan S. Netherton syndrome: successful use of topical tacrolimus and pimecrolimus in four siblings. Int J Dermatol. 2007;46:290-294. (Pubitemid 46390289)
35. Orlow SJ. Topical calcineurin inhibitors in pediatric atopic dermatitis: a critical analysis of current issues. Paediatr Drugs. 2007;9:1-11. (Pubitemid 47557111)
36. Beyerler M, Schmid-Grendelmeier P, Hafner J. Significantly elevated systemic levels after occlusive application of topical tacrolimus in atopic dermatitis. Dermatology. 2006;212:260-261.
37. Teshima D, Ikesue H, Itoh Y, et al. Increased topical tacrolimus absorption in generalized leukemic erythroderma. Ann Pharmacother. 2003;37:1444-1447. (Pubitemid 37205503)
38. Casson DH, Eltumi M, Tomlin S, et al. Topical tacrolimus may be effective in the treatment of oral and perineal Crohn's disease. Gut. 2000;47:436-440. (Pubitemid 30670841)
39. Russell RK, Richardson N, Wilson DC. Systemic absorption with complications during topical tacrolimus treatment for orofacial Crohn disease. J Pediatr Gastroenterol Nutr. 2001;32:207-208. (Pubitemid 32280639)
40. Thomson MA, Hamburger J, Stewart DG, et al. Treatment of erosive oral lichen planus with topical tacrolimus. J Dermatolog Treat. 2004;15:308-314. (Pubitemid 39423290)
41. Pitarch G, Torrijos A, Mahiques L, et al. Systemic absorption of topical tacrolimus in pyoderma gangrenosum. Acta Derm Venereol. 2006;86:64-65. (Pubitemid 46939794)
42. Ghislain PD, De Decker I, Lachapelle JM. Efficacy and systemic absorption of topical tacrolimus used in pyoderma gangrenosum. Br J Dermatol. 2004;150:1052-1053. (Pubitemid 38903559)
43. Allen DM, Esterly NB. Significant systemic absorption of tacrolimus after topical application in a patient with lamellar ichthyosis. Arch Dermatol. 2002;138:1259-1260. (Pubitemid 35025714)
44. Elidel [package insert]. East Hanover, NJ: Novartis Pharmaceuticals; 2007.
45. Allen BR, Lakhanpaul M, Morris A, et al. Systemic exposure, tolerability, and efficacy of pimecrolimus cream 1% in atopic dermatitis patients. Arch Dis Child. 2003;88: 969-973. (Pubitemid 37449400)
46. Eichenfield LF, Ho V, Matsunaga J, et al. Blood concentrations, tolerability and efficacy of pimecrolimus cream 1% in Japanese infants and children with atopic dermatitis. J Dermatol. 2007;34:231-236. (Pubitemid 46365243)
47. Harper J, Green A, Scott G, et al. First experience of topical SDZ ASM 981 in children with atopic dermatitis. Br J Dermatol. 2001;144:781-787. (Pubitemid 32374781)
48. Ling M, Gottlieb A, Pariser D, et al. A randomized study of the safety, absorption and efficacy of pimecrolimus cream 1% applied twice or four times daily in patients with atopic dermatitis. J Dermatolog Treat. 2005;16: 142-148. (Pubitemid 41364772)
49. Van Leent EJ, Ebelin M-E, Burtin P, et al. Low systemic exposure after repeated topical application of pimecrolimus (Elidel®), (SDZ ASM 981) in patients with atopic dermatitis. Dermatology. 2002;204:63-68. (Pubitemid 34136817)
50. Lakhanpaul M, Davies T, Allen BR, et al. Low systemic exposure in infants with atopic dermatitis in a 1-year pharmacokinetic study with pimecrolimus cream 1%*. Exp Dermatol. 2006;15:138-141.
51. Van Leent EJ, De Vries HJ, Ebelin ME, et al. Blood concentrations of pimecrolimus in adult patients with atopic dermatitis following intermittent administration of pimecrolimus cream 1% (Elidel) for up to 1 year. J Dermatolog Treat. 2007;18:19-22. (Pubitemid 46410632)
52. Draelos Z, Nayak A, Pariser D, et al. Pharmacokinetics of topical calcineurin inhibitors in adult atopic dermatitis: a randomized, investigator-blind comparison. J Am Acad Dermatol. 2005;53:602-609. (Pubitemid 41399926)
53. Yan A, Shah K, Kubrak C, et al. A pilot study of the efficacy and safety of pimecrolimus 1% cream in the treatment of Netherton syndrome: interim results. Abstract presented at the 65th Annual Meeting of American Academy of Dermatology, February 2-6, 2007; Washington, DC. Abstract P2401.
54. Oji V, Beljan G, Beier K, et al. Topical pimecrolimus: a novel therapeutic option for the comel-netherton syndrome. Abstract presented at the European Academy of Dermatology & Venereology 13th Congress, November 17-21, 2004; Florence, Italy; January 9-17, 2004; Hawaii.
55. Kane D, Barnes L, Fitzgerald O. Topical corticosteroid treatment: systemic side-effects. Br J Dermatol. 2003; 149:417. (Pubitemid 37100274)
56. Staab D, Pariser D, Gottlieb AB, et al. Low systemic absorption and good tolerability of pimecrolimus, administered as 1% cream (Elidel®) in infants with atopic dermatitis - a multicenter, 3-week, open-label study. Pediatr Dermatol. 2005;22:465-471. (Pubitemid 43961008)
57. Food and Drug Administration. Pediatric Advisory Committee. Discussion Topic: Risk Evaluation, Labeling, Risk Communication, and Dissemination of Information on Potential Cancer Risk Among Pediatric Patients Treated for Atopic Dermatitis With Topical Dermatological Immunosuppressants. Fujisawa Healthcare, Inc. February 15, 2005. Background Package. 1-30.
58. Akdis CA, Akdis M, Bieber T, et al. Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. J Allergy Clin Immunol. 2006;118:152-169. (Pubitemid 43946480)
59. Tofte S. Atopic dermatitis. Nurs Clin North Am. 2007;42: 407-419, vi.
60. Palmer CM, Lyon VB. Stepwise approach to topical therapy for atopic dermatitis. Clin Pediatr (Phila). 2008;47: 423-434. (Pubitemid 351624586)
61. Hammarstrom B, Wessling A, Nilsson JL. Pharmaceutical care for patients with skin diseases: a campaign year at Swedish pharmacies. J Clin Pharm Ther. 1995;20:327-334. (Pubitemid 26029926)
62. Zuberbier T, Orlow SJ, Palier AS, et al. Patient perspectives on the management of atopic dermatitis. J Allergy Clin Immunol. 2006;118:226-232. (Pubitemid 43946465)
63. Charman CR, Morris AD, Williams HC. Topical corticosteroid phobia in patients with atopic eczema. Br J Dermatol. 2000;142:931-936. (Pubitemid 30304603)
64. Charman C, Williams H. The use of corticosteroids and corticosteroid phobia in atopic dermatitis. Clin Dermatol. 2003;21:193-200. (Pubitemid 36629331)